Serina Therapeutics(SER.US)

Last Updated 19:00:00 ET
longbridge loading

Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks

Tip Ranks·
US
SER
-0.59%
US
XLV
+0.71%
US
IXJ
+0.77%
Tip Ranks·
US
SER
-0.59%
US
XLV
+0.71%
US
IXJ
+0.77%

Serina Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
SER
-0.59%
Earnings Watch·
US
SER
-0.59%

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | SER Stock News

StockTitan·
US
SER
-0.59%
US
PBE
+0.50%
US
XBI
+1.14%
StockTitan·
US
SER
-0.59%
US
PBE
+0.50%
US
XBI
+1.14%

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga_article·
US
QUCY
+19.15%
US
SLS
-18.78%
US
SER
-0.59%
benzinga_article·
US
QUCY
+19.15%
US
SLS
-18.78%
US
SER
-0.59%

Fatty15 Co-Founder, Dr. Stephanie Venn-Watson, Named 2026 LA Times Life Sciences Visionary

Unusual Whales·
US
SER
-0.59%
US
IHE
+1.08%
US
SBIO
+1.82%
Unusual Whales·
US
SER
-0.59%
US
IHE
+1.08%
US
SBIO
+1.82%

Serina names Srini Tenjarla CTO; raises CEO Steve Ledger's salary

TradingView·
US
SER
-0.59%
US
IXJ
+0.77%
US
IHE
+1.08%
TradingView·
US
SER
-0.59%
US
IXJ
+0.77%
US
IHE
+1.08%

NYSE Accepts Serina Therapeutics Continued Listing Compliance Plan

nasdaq·
US
ARKG
+3.32%
US
SER
-0.59%
US
XBI
+1.14%
nasdaq·
US
ARKG
+3.32%
US
SER
-0.59%
US
XBI
+1.14%
© 2026 Longbridge｜Disclaimer